Civica Rx

To Generic Drug Manufacturers Considering Retiring or Withdrawing ANDAs for Essential Medicines: Civica Rx Is Interested

Retrieved on: 
Tuesday, January 14, 2020
Pharmaceutical, Health, Other Health, Health, Pharmaceutical industry, Articles, Life sciences, Civica Rx, Abbreviated New Drug Application, Generic drug, New Drug Application, Medication, Essential medicines

Civica Rx (Civica, Inc.) today announced that it is interested in talking to generic drug manufacturers who are considering retiring or withdrawing their Abbreviated New Drug Applications (ANDAs) for essential medicines that are at risk of being in short supply.

Key Points: 
  • Civica Rx (Civica, Inc.) today announced that it is interested in talking to generic drug manufacturers who are considering retiring or withdrawing their Abbreviated New Drug Applications (ANDAs) for essential medicines that are at risk of being in short supply.
  • Part of our manufacturing strategy is to develop our own ANDAs for essential medications and that work is underway, said Martin VanTrieste, President and CEO of Civica Rx.
  • However, developing new ANDAs takes time and wed be very interested in taking over existing ANDAs for essential medications that have a history of drug shortages.
  • Developing Abbreviated New Drug Applications (ANDAs) for generic drugs and working with contract manufacturing organizations to produce Civica medications.

Civica Rx and Hikma Announce Shipments of Heparin and Seven Other Essential Injectable Medicines

Retrieved on: 
Tuesday, December 10, 2019
Oncology, Health, Hospitals, Surgery, Pharmaceutical, Cardiology, RTT, Civica Rx, Civica Rx, Hikma

Under the partnership with Civica Rx, announced last July, Hikma will produce 14 essential sterile injectable medications for Civica, using Hikma's Abbreviated New Drug Applications (ANDAs) and Civica's National Drug Code (NDC) and label.

Key Points: 
  • Under the partnership with Civica Rx, announced last July, Hikma will produce 14 essential sterile injectable medications for Civica, using Hikma's Abbreviated New Drug Applications (ANDAs) and Civica's National Drug Code (NDC) and label.
  • Hikma is the third largest US supplier by volume of generic injectable medicines with a growing portfolio of more than 100 injectable products.
  • Today, one in every six generic injectable medicines used in US hospitals is a Hikma product.
  • Civica aims to stabilize the supply of antibiotics, anesthetics, cardiac medications, pain management medications, and other essential sterile injectable medicines used in hospitals daily.

Patients Are Now Being Treated with a Civica Rx Medication

Retrieved on: 
Wednesday, October 2, 2019
Infectious diseases, Hospitals, Philanthropy, Biotechnology, Pharmaceutical, Health, Other Philanthropy, Chemistry, Civica, Physical sciences, Vancomycin, Natural sciences, Civica Rx, Vancomycin Hydrochloride for Injection, USP

Civica Rx (Civica, Inc.), the collaboration between three philanthropies and now 40 Health Systems representing over 1000 hospitals in 46 states, announced today that patients at Riverton Hospital in Utah are the first to receive a Civica medication, Vancomycin Hydrochloride for Injection, USP.

Key Points: 
  • Civica Rx (Civica, Inc.), the collaboration between three philanthropies and now 40 Health Systems representing over 1000 hospitals in 46 states, announced today that patients at Riverton Hospital in Utah are the first to receive a Civica medication, Vancomycin Hydrochloride for Injection, USP.
  • This is the first time a patient has been treated with a Civica Rx medication since the company was founded in September 2018.
  • This first delivery demonstrates the Civica model in action and is a dream come true, said Martin VanTrieste, President and CEO of Civica Rx.
  • We thank leading health systems across the country who founded or have since become members of Civica for their ongoing commitment and collaboration.

Civica Rx and Exela Pharma Sciences Join Forces to Provide Sodium Bicarbonate to Hospitals Across the U.S.

Retrieved on: 
Tuesday, September 10, 2019
General Health, Pharmaceutical, Philanthropy, Hospitals, Cardiology, Other Philanthropy, FDA, Health, Diabetes, Chemical substances, Chemistry, Physical sciences, Bicarbonates, Sodium compounds, Civica Rx, Sodium bicarbonate, Civica, Bicarbonate, Civica Rx, Exela Pharma Sciences

Civica Rx (Civica, Inc.) and Exela Pharma Sciences, LLC (Exela), today announce a long-term agreement to manufacture and supply Civica's growing membership of U.S. health systems with sodium bicarbonate injection, which has been in critically short supply in U.S. hospitals.

Key Points: 
  • Civica Rx (Civica, Inc.) and Exela Pharma Sciences, LLC (Exela), today announce a long-term agreement to manufacture and supply Civica's growing membership of U.S. health systems with sodium bicarbonate injection, which has been in critically short supply in U.S. hospitals.
  • Civica member hospitals have prioritized sodium bicarbonate as an urgent medical need because theyve had to ration use of the medication due to ongoing shortages.
  • Under the agreement, Exela will produce sodium bicarbonate for Civica, using Exelas Abbreviated New Drug Application (ANDA) and Civica's labeling and National Drug Code (NDC).
  • Sodium bicarbonate is a medicine that is a staple on hospital crash carts and often used for emergency resuscitations.

Hikma and Civica Rx sign long-term agreement to reduce generic drug shortages in the US

Retrieved on: 
Tuesday, July 23, 2019
Civica Rx, Abbreviated New Drug Application, Civica, RTT, Industries, Service industries

Under the agreement, Hikma will produce 14 essential sterile injectable medications for Civica as a private label distributor, using Hikma's Abbreviated New Drug Applications (ANDAs) and Civica's labeling and National Drug Code (NDC).

Key Points: 
  • Under the agreement, Hikma will produce 14 essential sterile injectable medications for Civica as a private label distributor, using Hikma's Abbreviated New Drug Applications (ANDAs) and Civica's labeling and National Drug Code (NDC).
  • Civica was founded in 2018 by leading US hospital systems concerned about generic drug shortages and philanthropic organizations passionate about improving healthcare.
  • Hikma is the third largest US supplier of generic injectable medicines with a growing portfolio of more than 100 injectable products.
  • "We applaud Hikma's clear commitment to reducing drug shortages," said Martin VanTrieste, President and CEO of Civica Rx.

Vizient to Collaborate with Civica Rx to Help Improve Drug Availability and Affordability by Providing Analytic Data into Provider Needs

Retrieved on: 
Monday, June 17, 2019
Practice Management, Health, Hospitals, Pharmaceutical, Medical Supplies, Articles, Economy, Business intelligence, Formal sciences, Civica Rx, Big data, Civica, Business, Analytics

Vizient announces that it is collaborating with Civica Rx to help reduce the impact of drug shortages.

Key Points: 
  • Vizient announces that it is collaborating with Civica Rx to help reduce the impact of drug shortages.
  • By providing insights into purchasing patterns and provider needs through its industry-leading analytics and data capabilities, Vizient will help Civica anticipate gaps in drug availability and affordability.
  • We applaud Vizient for helping to find innovative ways to reduce drug shortages through their analytics and data expertise, said Martin VanTrieste , Civica President and CEO.
  • This collaboration with Civica Rx is the latest effort by Vizient to improve accessibility and lower costs of pharmaceuticals.

Civica Rx and Xellia Pharmaceuticals Join Forces to Reduce Chronic Drug Shortages

Retrieved on: 
Wednesday, May 15, 2019
Health, Biotechnology, Pharmaceutical, Eli Lilly and Company, Chemistry, Peptides, Physical sciences, Civica Rx, RTT, Cyclic peptides, Civica, Pharmaceutical industry, Daptomycin, Vancomycin, Medication

Civica Rx (Civica, Inc.) and Xellia Pharmaceuticals today announced they have signed a product supply agreement under which Xellia will manufacture essential antibiotics, including Vancomycin and Daptomycin, for Civicas member health systems.

Key Points: 
  • Civica Rx (Civica, Inc.) and Xellia Pharmaceuticals today announced they have signed a product supply agreement under which Xellia will manufacture essential antibiotics, including Vancomycin and Daptomycin, for Civicas member health systems.
  • The partnership with Xellia will help avoid drug shortages and enable the supply security Civica and its member health systems are seeking.
  • Xellia will make medications for Civica under Xellias Abbreviated New Drug Application (ANDA) and Civica labeling and New Drug Code (NDC).
  • We are honored to work with Civica, an innovator in addressing generic drug shortages, said Carl-Aake Carlsson, CEO Xellia Pharmaceuticals.

Civica Rx Opens New Headquarters

Retrieved on: 
Friday, April 19, 2019
Health, Hospitals, Pharmaceutical, Philanthropy, Other Philanthropy, General Health, Civica Rx, Intermountain Healthcare, Civica, Intermountain, Ben McAdams, Service companies, Western United States, Industries

(Photo: Business Wire)

Key Points: 
  • (Photo: Business Wire)
    Joining the Civica Rx team in a grand opening ceremony and ribbon cutting were Utah Governor, Gary Herbert; U.S.
  • Congressman Ben McAdams (UT); Intermountain Healthcare CEO, Dr. Marc Harrison; University of Utah Senior Director Drug Information Services, Erin Fox; and Civica Rx Chairman of the Board and the brainchild of Civica Rx, Dan Liljenquist, who is also SVP of Strategy at Intermountain Healthcare.
  • Event speakers highlighted the challenges associated with generic drug shortages in the nations hospitals, shared enthusiasm about the promise of Civica Rx as an innovative, collaborative approach to stabilizing generic drug supply, and expressed pride in welcoming Civica Rx to Utah.
  • Civica Rx will act in the best interest of patients to eliminate uncertainty in the generic drug supplychain through long-term contracts with the health system members who have joined Civica Rx aswell as its manufacturing partners.